期刊文献+

肾上腺皮质增生患者的常见突变是该疾病新发生突变的热点区域 被引量:3

Common mutations of congenital adrenal hyperplasia are also the hotspots for new mutations
下载PDF
导出
摘要 目的对肾上腺皮质增生患者及家属(CAH)进行基因诊断并探讨其突变来源。方法通过限制性内切酶特异性识别突变位点的酶学方法对患者及其家系进行基因诊断。通过PCR测序的方法对收集到的家系进行DNA测序,分析确定肾上腺皮质增生致病基因21-羟化酶的突变。运用基因组短串联重复序列多态性(STR)分型技术进行亲缘关系分析,用以确定突变位点来源。结果患者(病例号7424)21-羟化酶基因存在I2g和I172N两个已知突变。I2g突变遗传自母亲(病例号7536),I172N系新发生突变。STR分析结果表明该患者的遗传物质一半来自母亲(病例号7536),一半来自父亲(病例号7535),二者系患者的生物学父母。结论肾上腺皮质增生疾病中出现的常见基因突变在遗传过程中也是新发生突变的热点区域。 Objective To discuss the genetic diagnosis of congenital adrenal hyperplasia(CAH) and investigate the resource of gene mutations in CAH.Method Enzymatic methods with restriction endonucleases that specifically recognized the mutation sites were used to detect the gene mutations in patients with CAH and their relatives.Polymerase chain reaction and direct sequencing were used to identify the mutations in 21-hydroxylase gene,and short tandem repeat(STR) typing was used to determine the sources of the mutations.Results One CAH patient had two known mutations in 21-hydroxylase gene,namely the I2g and I172N mutations.The former mutation was inherited from the biological mother and the latter was not inherited.Conclusion The 9 common mutations of CAH are also the hotspots for new mutations.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2012年第5期669-672,共4页 Journal of Southern Medical University
基金 教育部新教师基金(20090162120032) 湖南省科技计划项目(2010FJ3026)
关键词 肾上腺皮质增生 21-羟化酶 基因诊断 短串联重复序列多态性分型 congenital adrenal hyperplasia CYP21 genetic diagnosis short tandem repeat typing
  • 相关文献

参考文献9

  • 1Yu Y,Wang J,Huang X,et al.Molecular characterization of 25Chinese pedigrees with 21-hydroxylase deficiency[J].Genet TestMol Biomarkers,2011,15(3):137-142.
  • 2Barannik AP,Koltunova AA,Ozolinia LA,et al.A new DNAdiagnostic system for the detection of human CYP21 genemutations associated with adrenal cortex hyperplasia[J].Russian JBioorganic Chem,2010,36(3):354-65.
  • 3Singh RB.Quantitation of 17-OH-progesterone(OHPG)for diagno-sis of congenital adrenal hyperplasia(CAH)[J].Methods Mol Biol,2010,603:271-277.
  • 4Ramazani A,Kahrizi K,Razaghiazar M,et al.The frequency ofeight common point mutations in CYP21 gene in Iranian patientswith congenital adrenal hyperplasia[J].Iran Biomed J,2008,12(1):49-53.
  • 5Asanuma A,Ohura T,Ogawa E,et al.Molecular analysis ofJapanese patients with steroid 21-hydroxylase deficiency[J].J HumGenet,1999,44(5):312-317.
  • 6Yokoyama Y,Teraoka M,Tsuji K,et al.Rapid screening method todetect mutations in CYP21,the gene for 21-hydroxylase[J].Am JMed Genet,2000,94(1):28-31.
  • 7姚林方,叶章群,陈志强,郭宏骞,甘卫东.靶向STAT3的decoy核酸抑制膀胱癌细胞生长的实验研究[J].实用临床医药杂志,2009,13(11):1-4. 被引量:1
  • 8张景亮,程晓丽,刘淑莲,曹玉媛,封青川,徐朝阳.线粒体DNA3243、3316、3394位点突变与精神分裂症相关分析[J].第二军医大学学报,2011,32(2):179-181. 被引量:4
  • 9张波,陆召麟,王玥,陶红.中国人21-羟化酶缺乏症基因型和临床表型特点研究[J].Acta Genetica Sinica,2004,31(9):950-955. 被引量:17

二级参考文献20

  • 1于珮,于德民,刘德敏,王琨,汤新之.Relationship between mutations of mitochondrial DNA ND1 gene and type 2 diabetes[J].Chinese Medical Journal,2004(7):985-989. 被引量:12
  • 2唐春,别平,李昆,张玉君,马正伟.梗阻性黄疸大鼠肝细胞线粒体DNA损伤的定量研究[J].第二军医大学学报,2007,28(1):48-52. 被引量:13
  • 3Jing N, Tweardy D J. Targeting Stat3 in cancer therapy[J]. Antieancer Drugs, 2005, 16: 601.
  • 4Leong P L, Andrews G A, Johnson D E, et al. Targeted inhibition of Star3 with a decoy oligonucleotide abrogates head and neck cancer cell growth[J]. Proc Natl Acad Sci U S A, 2003, 100: 4138.
  • 5Garcia R, Yu C L, Hudnall A, etal. Constitutive activation of Star3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells [J]. Cell Growth Differ, 1997, 8: 1267.
  • 6Oh Y M, Kim J K, Choi Y, et al. Prediction and experimental validation of novel STAT3 target genes in human cancer cells[J]. PLoS One, 2009, 4(9): e6911.
  • 7Levy D E, Damell JE Jr. Stats: transcriptional control and biological impact[J]. Nat Rev Mol Cell Biol, 2002, 3: 651.
  • 8Hodge D R, Hurt E M, Farrar W L. The role of IL - 6 and STAT3 in inflammation and cancer[J ]. Eur J Cancer, 2005, 41 : 2502.
  • 9He M, Young C Y. New approaches to target the androgen receptor and STAT3 for prostate cancer treatments[J ]. Mini Rev Med Chem, 2009, 9(3): 395.
  • 10Zhang X, Zhang J, Wang L, et al. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice[J ]. BMC Cancer, 2007, 7 : 149.

共引文献19

同被引文献11

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部